Pegasus Biotech and VIDO Announce Strategic Collaboration to Advance Commercialization of the BPE DNA Platform

[Charlottetown, PE, Canada]: Pegasus Biotech Inc. is pleased to announce a strategic collaboration with the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) to advance the development and commercialization of Pegasus’s BPE DNA platform for next-generation biologics.

This collaboration brings together Pegasus’ innovative BPE DNA platform with VIDO’s globally recognized expertise in infectious disease research and vaccine development.

The collaboration, formalized a memorandum of understanding, is structured around Pegasus’ expertise in BPE plasmid development, together with VIDO’s manufacturing capabilities and infrastructure. By leveraging VIDO’s experience and facilities, Pegasus Biotech will further strengthen its ability to help clients bridge the gap between early platform development and commercial application.

Together, Pegasus and VIDO aim to provide a more complete pathway for the development and production of products enabled by the BPE DNA platform. This collaboration is expected to support Pegasus’ clients in accelerating commercialization opportunities across animal and human vaccines, gene therapy, and drug delivery applications.

“This collaboration represents an important step forward for Pegasus Biotech and for the continued advancement of the BPE DNA platform,” said Yimy Mena, CEO of Pegasus Biotech Inc. “By working with VIDO, we are strengthening our ability to support clients with the expertise, manufacturing capabilities, and infrastructure needed to move innovative products closer to commercialization.”

The Memorandum of Understanding establishes a three-year framework to encourage and support future collaboration between the parties, with specific projects to be defined under separate agreements